Stephens analyst Scott Fidel lowered the firm’s price target on Universal Health to $140 from $155 and keeps an Equal Weight rating on the shares following the company’s Q4 report. Universal Health anticipates that revenues should grow at a "relatively normal" 6% rate in 2023, but operating leverage is not expected to materialize again this year, the firm tells investors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on UHS:
- Universal Health downgraded to Peer Perform from Outperform at Wolfe Research
- Universal Health falls -10.5%
- UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND 2023 FULL YEAR EARNINGS GUIDANCE
- Universal Health sees FY23 adjusted EPS of $9.50-$10.50, consensus $10.79
- Universal Health reports Q4 adjusted EPS $3.02, consensus $2.96
